MedTrace Logo

Budesonide Treatment for Lymphocytic Colitis

NCT00180050 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-03-30

No results posted yet for this study

Summary

The purpose of this study is to determine whether orale budesonide is effective in the treatment of lymphocytic colitis

Conditions

  • Microscopic Colitis

Interventions

DRUG

Budesonide

Sponsors & Collaborators

  • Dr. Falk Pharma GmbH

    collaborator INDUSTRY

  • Technische Universität Dresden

    lead OTHER

Principal Investigators

  • Stephan Miehlke, Prof. · Medical Department I, Technical University Hospital, Dresden, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-01-31
Primary Completion
2006-08-31
Completion
2007-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00180050 on ClinicalTrials.gov